There are currently 1493 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years
NCT04821310
Recruiting
The purpose of this study is to explore the outcomes, tolerability and safety of 2 different doses of oral pantoprazole (full healing dose, half healing dose), assigned based upon weight, for the maintenance of healing of erosive esophagitis in pediatric participants aged 1 to 17 years with endoscopically-confirmed, healed erosive esophagitis.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
10/11/2024
Locations: Children's Health / Children's Medical Center, Dallas, Texas
Conditions: Esophagitis
Register for Updates
Impella RP Flex with Smart Assist
NCT06637644
Recruiting
To capture observational data of the Abiomed Impella RP Flex in a real-world setting.
Gender:
ALL
Ages:
All
Trial Updated:
10/09/2024
Locations: Medical City Heart Hospital Dallas, Dallas, Texas +1 locations
Conditions: Right Ventricular (RV) Dysfunction
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: VA North Texas Medical Center, Dallas, Texas
Conditions: Heart Failure
Register for Updates
Fall Risk and Quality of Life: in Individuals With Cancer Treatment Related Peripheral Neuropathy.
NCT06313359
Recruiting
The purpose of this research is to examine the impact of peripheral neuropathy on fall risk and quality of life in people who had cancer and neuropathy from cancer treatments. The investigators are interested to find out if the participant have any difficulty with thinking, feeling, balancing, or moving around that will contribute to risk for falls or quality of life. Investigators are also interested to see if the participants have any difficulty with doing two activities at the same time, such... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Texas Woman's University, Dallas, Texas
Conditions: Peripheral Neuropathy Due to Chemotherapy
Register for Updates
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
NCT01623076
Recruiting
This study seeks to determine the biologic causes of inflammation in patients with Transverse Myelitis (TM) Neuromyelitis Optica Spectrum Disorder (NMOSD) and related conditions. While patients will be treated according to decisions with their treating physician, this study will collect data and samples from patients prospectively to gain a better understanding of the disease. We are seeking to understand why some patients respond to medications, while others do not. We also seek to understand w... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
10/07/2024
Locations: The University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Optic Neuritis
Register for Updates
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
NCT06008275
Recruiting
The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial will evaluate one dosing schedule of neratinib in ruxolitinib in patients with metTNBC with locoregional recurrence.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
Register for Updates
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
NCT05518188
Recruiting
MELPIDA is proposed for the treatment of subjects with SPG50 and targets neuronal cells to deliver a fully functional human AP4M1 cDNA copy via intrathecal injection to counter the associated neuronal loss. Outcomes will evaluate the safety and tolerability of a single dose of MELPIDA, which will be measured by the treatment-associated adverse events (AEs) and serious adverse events (SAEs). Secondarily, the trial will explore efficacy in terms of disease burden assessments.
Gender:
ALL
Ages:
Between 4 months and 10 years
Trial Updated:
10/04/2024
Locations: Children's Medical Center Dallas, Dallas, Texas
Conditions: Spasticity, Muscle, Microcephaly, Intellectual Deficiency, Growth Retardation, SPG50, Spastic Paraplegia
Register for Updates
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
NCT03671889
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
10/04/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Alzheimer Disease
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas, Texas +1 locations
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
NCT05755035
Recruiting
The main aim of this study is to evaluate the PK, safety, tolerability and immunogenicity of subcutaneous (SC) administration of TAK-881 in adult and pediatric participants with PIDD and compare them to HYQVIA in participants 16 years old and older. The participants will be treated with TAK-881/HYQVIA or HYQVIA/TAK-881 with the same dose and dosing interval of immunoglobulin for up to 51 weeks (for participants greater than or equal to \[\>=\]16 years) and only with TAK-881 for up to 27 weeks (... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
10/04/2024
Locations: Allergy Partners of North Texas, Dallas, Texas
Conditions: Primary Immunodeficiency Diseases (PID)
Register for Updates
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765
Recruiting
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Register for Updates
Add-on Reparixin in Adult Patients With ARDS
NCT05496868
Recruiting
Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). 2. to assess the effect of reparixin on systemic biomarkers linked to a hyper-inflammatory ARDS phenotype. 3. To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Acute Respiratory Distress Syndrome, Adult
Register for Updates